Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsA trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.
A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.
Q1 2026 Preview: 5 FDA Decisions to Watch in Specialty Care
1.
Coffee, Tea Tied to Lower Risk of Head and Neck Cancer
2.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
3.
Investigations may result in novel combination therapies for early-stage lung cancers.
4.
Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.
5.
Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC
1.
Hope for a Cure: Exploring New Treatments for Sickle Cell Anemia
2.
Understanding Protein C Deficiency: Symptoms, Causes, and Treatment
3.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
4.
AI in Cancer Diagnostics and Imaging Interpretation
5.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
2.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation